The Role of DDX41 in MDS
2019
Overview
The Vera and Joseph Dresner Foundation granted The Cleveland Clinic Foundation a $500,000 grant over two years for established investigator Dr. Richard A. Padgett.
Details
Dr. Padgett’s research will attempt to show the use of the characterization of DDX41 perturbed cells and animals provide rational targets for therapeutic approaches to treat splicing factor mutated MDS.
Learn more about The Cleveland Clinic Foundation